Management of Ipilimumab-Induced Fever
Fever from ipilimumab should be managed by first ruling out infection and immune-related adverse events (irAEs), then treating based on severity: isolated low-grade fever without other symptoms can be monitored while continuing therapy, but fever with systemic symptoms or organ dysfunction requires holding ipilimumab and initiating corticosteroids at 0.5-2 mg/kg/day prednisone equivalent depending on grade.
Initial Assessment and Workup
When fever develops in a patient on ipilimumab, immediately evaluate for:
- Infectious causes: Blood cultures, urinalysis, chest imaging, and COVID-19 testing per institutional protocols 1
- Specific irAE patterns: Fever commonly accompanies immune-related colitis, hepatitis, pneumonitis, hypophysitis, or adrenal insufficiency 2, 3
- Timing: Median onset of irAEs is approximately 7 weeks after ipilimumab initiation, though can occur 1-48 weeks after starting therapy 4
Key Clinical Clues
Look for accompanying symptoms that suggest specific irAEs:
- Diarrhea (>4 stools/day): Suggests immune-related colitis - requires colonoscopy 5, 6
- Transaminitis: Suggests immune-related hepatitis 7
- Dyspnea/cough: Suggests pneumonitis - obtain CT chest 1
- Hyponatremia: May indicate hypophysitis, adrenal insufficiency, or SIADH 3
- Cognitive changes/confusion: Consider encephalitis - requires lumbar puncture 8
Grading and Management Algorithm
Grade 1 Fever (Isolated, <38.3°C, no other symptoms)
- Continue ipilimumab with close monitoring
- Weekly clinical assessment
- Rule out infection with basic workup
- Monitor for development of other irAE symptoms 1
Grade 2 Fever (38.3-40°C or fever with mild systemic symptoms)
- Hold ipilimumab
- Complete infectious and irAE workup as above
- If isolated fever without organ dysfunction: Prednisone 0.5-1 mg/kg/day orally 1
- If fever accompanies Grade 2 organ-specific irAE (e.g., colitis, hepatitis): Treat the underlying irAE per guidelines 5
- Consider permanent discontinuation if steroid-refractory
Grade 3-4 Fever (>40°C or fever with severe organ dysfunction)
- Permanently discontinue ipilimumab 1
- Admit patient for monitoring
- IV methylprednisolone 1-2 mg/kg/day 1, 7
- Aggressive infectious workup including blood cultures, imaging
- Treat underlying organ-specific irAE (colitis, hepatitis, pneumonitis, etc.) per specialty guidelines
- If steroid-refractory after 48-72 hours: Add infliximab, mycophenolate mofetil, or IVIG depending on the specific irAE 1, 8
Critical Pitfalls to Avoid
Do not empirically start high-dose steroids in febrile neutropenia without first ruling out infection - this is particularly important in patients receiving combination chemotherapy/ipilimumab regimens 9. The standard neutropenic fever pathway applies first.
Do not assume fever is always infectious - ipilimumab-induced fever can be non-infectious and immune-mediated, especially when combined with CTLA-4 inhibitors 10. However, infection must always be excluded first.
Do not delay endoscopy if diarrhea is present - fever with diarrhea in ipilimumab patients warrants urgent colonoscopy to assess for immune-related colitis, as this can rapidly progress to perforation 5, 6.
Special Considerations for Combination Therapy
When ipilimumab is combined with nivolumab (anti-PD-1), the risk of pyrexia increases significantly (OR 2.48) compared to CTLA-4 inhibitors alone 10. These patients require:
- Lower threshold for workup and intervention
- Higher suspicion for multiple concurrent irAEs
- More aggressive monitoring during steroid taper 11
Steroid Tapering
Once fever resolves and underlying irAE improves:
- Taper steroids slowly over 4-6 weeks minimum
- Monitor for irAE recurrence during taper
- Do not restart ipilimumab if Grade 3-4 irAE occurred 1, 5
The key principle is that fever is rarely an isolated finding - it typically signals an underlying immune-related process requiring organ-specific evaluation and management 3, 4.